The BLA (Biologics License Application) for the “HPC-Cord Blood” product, was submitted to FDA on January 7th, 2022, and StemCyte was officially notified on March 8th, 2022, that the submission was acceptable to enter the biologics license quality review process. The “HPC-Cord Blood” is an umbilical cord blood hematopoietic stem cell product intended for unrelated…
eTurboNews greinar eru eingöngu fyrir áskrifendur. Áskrift er ÓKEYPIS.
Skrá inn Smelltu hér til að gerast áskrifandi ÓKEYPIS
Skrá inn Smelltu hér til að gerast áskrifandi ÓKEYPIS
HVAÐ Á AÐ TAKA ÚR ÞESSARI GREIN:
- Product, was submitted to FDA on January 7th, 2022, and StemCyte was officially notified on March 8th, 2022, that the submission was acceptable to enter the biologics license quality review process.
- Is an umbilical cord blood hematopoietic stem cell product intended for unrelated….
- The “HPC-Cord Blood”.
